雲頂新耀-B(1952.HK)首日上市收漲32.27% 市值突破200億港元 高瓴淡馬錫為股東
格隆匯10月9日丨雲頂新耀-B(1952.HK)今日首日上市高開28.27%,盤中最高漲37.27%報75.5港元,最終收漲32.27%報72.75港元,成交30.79億港元,全天換手率15.02%,最新總市值206億港元。公司本次IPO定價為55港元,募集資金淨額約32.841億港元。雲頂新耀是一家專注於創新藥開發及商業化的生物製藥公司,此次IPO共有16名基石投資者,共認購2.25億美元,包括RA Capital、建峖實業投資(Janchor Partners)、新加坡政府投資公司(GIC)、貝萊德基金(BlackRock)、高瓴(Hillhouse Capital)、清池資本(Lake Bleu)、奧博資本(Orbimed)等。雲頂新耀是繼嘉和生物、泰格醫藥、甘李藥業、康基醫療、海吉亞醫療之後,又一家上市的高瓴投資的生物醫藥企業。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.